Prils Market Size & Share, by Type (Amipril, Quinapril, Cilazapril, Benazepril); Distribution Channel (Hospital, Pharmacies); Application (Hypertension, Heart Failure, Chronic Kidney Disorder) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4109
  • Published Date: Aug 08, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023 - 2035

Prils Market size is projected to reach USD 4 Billion by the end of 2035, growing at a CAGR of 6% during the forecast period, i.e., 2023 – 2035. In the year 2022, the industry size of prils was around USD 2 Billion. The growth of the market can be attributed to the increasing prevalence of high blood pressure. Lifestyle modifications and appropriate medication, such as prils, are frequently used to treat the disease.

When more people are diagnosed with hypertension and given prescriptions for blood pressure management, in turn, could increase the demand for market. According to estimates over 69 million senior adults in India are expected to have hypertension by the year 2050.

Factors that are believed to fuel the prils market growth include the rise in the pharmaceutical industry across the globe. As more people gain access to the medication, there may be an increase in demand as a result of greater accessibility and availability of prils in hospitals, pharmacies, and other locations.


Prils Market
Get more information on this report: Request Free Sample PDF

Prils Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Prevalence of Lifestyle Disorders – As more people with lifestyle disorders rely on drugs to manage their illnesses, the prils market is expected to expand more in the upcoming years. According to the WHO, non-communicable diseases, or NCDs—of which lifestyle illnesses are a subset—take the lives of more than 4o million people each year, or more than 65% of all fatalities worldwide.
  • Rising Geriatric Population – Age-related changes in blood vessel flexibility, kidney function, and lifestyle choices all raise the risk of hypertension in older persons. Thus the expanding older population may face a higher prevalence of hypertension, which as a result is estimated to drive market growth. Lately over 8% of the world's population, is over the age of 65. By 2050, this figure is expected to rise by over 15% of the world's population.
  • Growing Incidences of Cardiovascular Diseases – It is expected that CVD can develop as a result of unhealthy lifestyle habits including an unhealthy diet, excessive sitting, and a lack of exercise, which is anticipated to drive the prils market growth. It was discovered that with over 17 million deaths per year, cardiovascular diseases (CVDs) are the leading cause of death worldwide.

Challenges

  • The challenge to getting Approval from Regulatory Authorities - The acquirement of approval for the production and testing of the product is one of the major factors predicted to slow down the market growth. For instance, it could take a lengthy time to obtain regulatory authorities' clearance, which delays the release of the product.
  • Development of Fake Medicines by Several Companies
  • Exorbitant Cost of Drugs

Prils Market: Key Insights

Base Year

2022

Forecast Year

2023-2035

CAGR

~6%

Base Year Market Size (2022)

~ USD 2 Billion

Forecast Year Market Size (2035)

~ USD 4 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Prils Segmentation

Application (Hypertension, Heart Failure, Chronic Kidney Disorder)

The hypertension segment is estimated to hold 50% share of the global prils market in the year 2035. The growth of the segment can be attributed to the increasing cases of hypertension across the globe. As more individuals with hypertension may need medications to control their blood pressure, this could lead to an increase in demand for market.

Besides prils are frequently combined with other antihypertensive drugs to improve blood pressure control which is further expected to contribute to the market growth. Around 970 million people worldwide, or over 25% of the population, have hypertension, and by 2025, that number is projected to rise by over 28%.

Distribution Channel (Hospital, Pharmacies)

Prils market from the hospital segment is expected to garner a significant share of 40% in the year 2035. Prils may be prescribed in hospitals for patients with comorbidities, such as diabetes or chronic renal disease that are frequently linked to hypertension or heart failure. They may be provided as part of the therapy plan for various comorbidities since many individuals admitted to hospitals may have several medical problems. As a result, the demand for prils in hospitals may be expanding along with the prevalence of these comorbidities. As a consequence, multiple opportunities for the segment's growth are expected in the next years.

Our in-depth analysis of the global prils market includes the following segments:

           Type

  • Amipril
  • Quinapril
  • Cilazapril
  • Benazepril

          Distribution Channel 

  • Hospital
  • Pharmacies

            Application

  • Hypertension
  • Heart Failure
  • Chronic Kidney Disorder

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Prils Industry - Regional Synopsis

North American Market Forecast

The prils market in North America is projected to be the largest with a share of about 41% by the end of 2035. The growth of the market can be attributed majorly to the increasing cases of obesity. For instance, the chance of developing hypertension and other cardiovascular disorders increases with obesity, which could result in a rise in the demand for hypertension drugs.

Further, the growing healthcare infrastructure in the region, along with the high prevalence of neurological disorders, is also anticipated to contribute to the market growth in the region. According to estimates, between 2017 and 2020, more than 40% of US people were obese, making it one of the most prevalent health issues in the country.

European Market Statistics

The prils market in Europe is estimated to hold the second-largest share of 31% by the end of 2035. The growth of the market can be attributed majorly to the increasing initiatives to assist the expansion of generic medications through pricing and reimbursement. Generic prils may be used more frequently as a result, which could raise demand for these drugs.

In addition, the region's favorable government policies and surging expenditure on research and development activities are also anticipated to boost market growth during the forecast period.

Research Nester
Prils Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Prils Market

top-features-companies
    • Teva Pharmaceuticals Industries Ltd.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Boehringer Ingelheim International GmbH
    • Sun Pharmaceuticals Industries Ltd.
    • Pfizer Inc.
    • Mylan N.V
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Manus Aktteva Biopharma LLP
    • Canagen Pharmaceuticals Inc.
    • Lupin Limited

In the News

  • Lupin Limited entered into a contract with Medis for Lupin’s orphan drug NaMuscla (mexiletine). Further, for the symptomatic management of people with non-dystrophic myotonic (NDM) diseases, Medis will market NaMuscla in Central and Eastern European nations.
  • Novartis AG collaborated with Dr. Reddy's Laboratories which is exclusive for certain of its well-known medications, such as the Voveran range, the Calcium range, and Methergine. Further, the agreement aims to increase patient’s access to these medications beyond present geographic boundaries.

Author Credits:  Radhika Pawar


  • Report ID: 4109
  • Published Date: Aug 08, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising geriatric population and the growing incidences of cardiovascular diseases are the major factors driving the market growth

The market size of prils is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2023 – 2035.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Novartis AG, Manus Aktteva Biopharma LLP, Canagen Pharmaceuticals Inc., and Lupin Limited., and others.

The hypertension segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Prils Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying